| Literature DB >> 33388371 |
Lu Wang1, Xiao Xiong1, Zhimeng Yao1, Jianlin Zhu1, Yusheng Lin2, Wan Lin3, Kai Li1, Xiaozheng Xu4, Yi Guo5, Yuping Chen6, Yunlong Pan1, Fuyou Zhou7, Jun Fan8, Yan Chen8, Shegan Gao9, Sai-Ching Jim Yeung10, Hao Zhang11.
Abstract
Transcription-induced chimeric RNAs are an emerging area of research into molecular signatures for disease biomarker and therapeutic target development. Despite their importance, little is known for chimeric RNAs-relevant roles and the underlying mechanisms for cancer pathogenesis and progression. Here we describe a unique ASTN2-PAPPAantisense chimeric RNA (A-PaschiRNA) that could be the first reported chimeric RNA derived from the splicing of exons and intron antisense of two neighboring genes, respectively. Aberrant A-PaschiRNA level in ESCC tissues was associated with tumor progression and patients' outcome. In vitro and in vivo studies demonstrated that A-PaschiRNA aggravated ESCC metastasis and enhanced stemness through modulating OCT4. Mechanistic studies demonstrated that ERK5-mediated non-canonical PAF1 activity was required for A-PaschiRNA-induced cancer malignancy. The study defined an undocumented function of chimeric RNAs in aggravating cancer stemness and metastasis.Entities:
Keywords: Chimeric RNA; Esophageal squamous cell carcinoma; Metastasis; Stemness
Year: 2020 PMID: 33388371 DOI: 10.1016/j.canlet.2020.10.052
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679